Scientific African (Sep 2024)
Involvement of catecholaminergic and nitric oxide–cGMP pathways in the antidepressant-like effects of hydroethanolic leaf extract of Morinda Longiflora G. Don in Mice
Abstract
Depression is a major world health issue. Though conventional antidepressants are employed for its management, they are fraught with inconsistent efficacy and untoward side effects. Therefore, finding alternative medicines for depression treatment is critical. The present study evaluated the possible antidepressant-like properties of hydroethanolic leaf extract of Morinda longiflora (MLE) in animal models. Acute animal models—Forced swim (FST) and tail suspension tests (TST)—as well as a chronic model, open space swim test, were used to establish antidepressant-like activity. The open field test was performed to exclude confounding psychostimulatory effects. Attempts were also made to investigate the possible underlying mechanism(s) of the antidepressant-like action of MLE. Oral treatment with MLE (30–300 mg/kg) significantly decreased the duration of immobility in the TST and FST. Also, treatment of mice with para-chlorophenylalanine (PCPA, 300 mg/kg, i.p.) failed to reverse the reduction in immobility duration induced by MLE. Furthermore, after treating mice with reserpine (1 mg/kg), α-methyl-p-tyrosine (AMPT, 100 mg/kg, i.p.), or both drugs combined, the reduction in immobility duration caused by MLE was reversed. Again, the anti-immobility actions produced by the extract were significantly reversed by l-arginine, sildenafil, haloperidol and prazosin but not propranolol, yohimbine or cyproheptadine. Pre-treatment of mice with l-NAME and methylene blue potentiated the anti-immobility action produced by the extract. The extract markedly reduced the duration of immobility in the OSST model. However, the extract (30–300 mg/kg) had no significant effect on the total distance travelled in the open field test. In conclusion, the current findings suggest that hydroethanolic leaf extract of Morinda longiflora has significant antidepressant-like activity and may involve catecholaminergic and nitric oxide-cyclic guanosine monophosphate pathways.
